Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 3, 2016
- Oral and poster presentations span multiple hematologic diseases including myelodysplastic syndromes, beta-thalassemia and myelofibrosis - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, developme...
Nov 2, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will present at the 25th Annual Cred...
Oct 27, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live conference call and webcas...
Oct 13, 2016
Webcast to be held October 28, 2016 at 10:00 a.m. EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases,...
Sep 27, 2016
- Habib Dable Appointed as President and CEO - - Leadership Transition Highlights Acceleron's Progression to its Next Stage of Growth - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the ...
Aug 31, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming ...
Aug 4, 2016
- Presented positive data that confirms and extends longer term Phase 2 safety and efficacy results for luspatercept in myelodysplastic syndromes and beta-thalassemia - - Presented positive Phase 1 ACE-083 results showing increases in muscle volume in the tibialis anterior muscle in healthy volunt...
Jul 28, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a ...
Jul 25, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced the appointment of the experi...
Jul 8, 2016
-ACE-083 increased muscle volume of the tibialis anterior muscle by 8.9% in healthy volunteers- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidate...
Jun 29, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that results from the Phase 1...
Jun 10, 2016
- Preliminary results show that treatment with investigational drug luspatercept results in clinically meaningful increases in hemoglobin and durable transfusion independence in patients with lower risk myelodysplastic syndromes - - Acceleron to host conference call and live webcast today at 8:00 ...
Jun 10, 2016
- Longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden, and improved patient reported quality of life measures in patients with beta-thalassemia - - Acceleron to host conference call and live webcast today...
Jun 7, 2016
Management to review highlights from presentations of ongoing Phase 2 clinical trials in MDS and beta-thalassemia CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic ...
Jun 1, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that senior management will ...
= add release to Briefcase